ModernMedicine Resource Center More Topics

Bladder Cancer Resource Center

Novel bladder Ca agent shows promise in phase II trialAn investigatory bladder cancer agent was associated with a 12-month high-grade recurrence-free survival of 35% for patients with Ta/T1 disease, researchers reported.
Immunotherapy approved for advanced urothelial CaNivolumab (Opdivo) is the second in class of immune checkpoint inhibitors approved for advanced bladder cancer—treatments that are having “tremendous responses across a spectrum of cancers,” says Leonard G. Gomella, MD.
PD-L1 inhibitor shows promise as first-line therapy
PD-L1 inhibitor shows promise as first-line therapyA recently approved treatment for urothelial carcinoma provides durable responses when used as first-line treatment in patients who are ineligible for cisplatin-based therapy, according to a recent study.
Uro Pipeline: Bladder Ca drug-device combination begins second phase Ib trialA bladder cancer drug-device combination, a localized prostate cancer agent, and a new surgical robot are among other treatments in the pipeline discussed in this round-up.
Study data may help risk stratify microhematuria DxA recent study of patients with a new diagnosis of microhematuria finds that rates of bladder and kidney cancer as well as urolithiasis depend on how thoroughly the patients are evaluated.
Bladder cancer surveillance: Challenges and opportunitiesIn her latest blog post, Adele M. Caruso, MSN, CRNP, discusses challenges related to bladder cancer surveillance and how they can be overcome.
Bladder Ca linked to risk of second primary cancerAmong survivors of the most common types of cancer, bladder cancer survivors have the highest risk for developing a second primary cancer, according to a recent study.
Bladder Ca guide provides risk-stratified frameworkA recently released guideline on diagnosis and treatment of nonmuscle-invasive bladder cancer from the AUA and the Society of Urologic Oncology provides practitioners with a risk-stratified clinical framework to aid treatment decisions and surveillance strategies, said Sam S. Chang, MD, MBA.